An experimental mRNA vaccine for the COVID-19 virus generated a strong immune response in older adults in a phase 1 clinical trial, who generally tolerated it well, the National Institutes of Health reports.

The National Institute of Allergy and Infectious Diseases developed the vaccine with Moderna Inc.

The phase 1 trial began in March and later added 40 healthy adults over age 55, who received two doses and will be followed for a year to monitor the long-term effects of the vaccine. According to the researchers, the results support testing the vaccine in older adults in an ongoing large Phase 3 trial.

Related News Articles

Perspective
We’ve been discussing for months how hospitals and health systems are contending with the worst financial crisis in their history as they continue to serve on…
Headline
The Centers for Medicare & Medicaid Services yesterday issued a final rule updating the home health prospective payment system for calendar year 2021.…
Headline
The Federal Reserve Board today reduced the minimum loan size for three Main Street Lending Program facilities from $250,000 to $100,000 and adjusted…
Headline
“The COVID-19 pandemic has proved that crisis tends to be a driver of innovation,” writes Jonathan Bandel, vice president of strategy and innovation for New…
Headline
The Food and Drug Administration Wednesday updated its guidance on enforcement policy for non-invasive remote monitoring devices that support patient…
Headline
Over 10,000 eligible nursing homes, or 76% of the field, will receive a portion of $333 million in COVID-19 Provider Relief Funds for meeting infection control…